Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Harrison, G L Abby ^a,b   Pryor, Jan ^b,c   Malani, Joji ^c   Supuri, Mathias ^d   Masta, Andrew ^e   Teriboriki, Burentau ^f   Toatu, Tebuka ^g   Penny, David ^h   Allain, Jean Pierre ⁱ   Barnes, Eleanor ^a   Pybus, Oliver G ^j   Klenerman, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WalterEliza Hall Institute for Medical Research ^*  (United States)

^c FIJI NATIONAL UNIVERSITY   (Fiji)

^d Pacific International Hospital   (Papua New Guinea)

^e UNIVERSITY OF PAPUA NEW GUINEA   (Papua New Guinea)

^f Tabiteuea Hospital   (Kiribati)

^g Secretariat of the Pacific Community   (Fiji)

^h MASSEY UNIVERSITY   (New Zealand)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; VIRUS RNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; FEMALE; FIJI; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEPATITIS C VIRUS; HEPATITIS C VIRUS INFECTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INFANT; KIRIBATI; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; PACIFIC ISLANDS; PAPUA NEW GUINEA; POPULATION RESEARCH; PREVALENCE; RNA VIRUS INFECTION; SCHOOL CHILD; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; FIJI; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKINS; MALE; MICRONESIA; MIDDLE AGED; PAPUA NEW GUINEA; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES;

EID: 84882624003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066749     Document Type: Article

References (43)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362 doi:10.1126/science.2523562.
2. Choo QL, Richman KH, Han JH, Berger K, Lee C, et al. (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci 88: 2451-2455.
3. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74 (Pt 11):: 2391-2399 doi:10.1099/0022-1317-74-11-2391.
4. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, et al. (2007) Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 45: 1102-1112 doi:10.1128/JCM.02366-06.
5. Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A, (2003) The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 20: 381-387 doi:10.1093/molbev/msg043.
6. Simmonds P, (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188 doi:10.1099/vir.0.80401-0.
7. Nakano T, Lu L, Liu P, Pybus OG, (2004) Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis 190 (6):: 1098-1108 doi:10.1086/422606.
8. Nakano T, Lu L, He Y, Fu Y, Robertson BH, et al. (2006) Population genetic history of hepatitis C virus 1b infection in China. J Gen Virol 87: 73-82 doi:10.1099/vir.0.81360-0.
9. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, et al. (2009) The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 6 (12):: e1000198 doi:10.1371/journal.pmed.1000198.
10. Ponde RA, (2011) Hidden hazards of HCV transmission. Med Microbiol Immunol 200: 7-11 doi:10.1007/s00430-010-0159-9.
11. Candotti D, Temple J, Sarkodie F, Allain JP, (2003) Frequent recovery and broad genotype 2 diversity characterize Hepatitis C virus infection in Ghana, West Africa. J Virol 77: 7914-7923 doi:10.1128/JVI.77.14.7914-7923.2003.
12. Utama A, Budiarto BR, Monasari D, Octavia TI, Chandra IS, et al. (2008) Hepatitis C virus genotype in blood donors and associated liver disease in Indonesia. Intervirology 51: 410-416 doi:10.1159/000205515.
13. Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, et al. (2009) Genetic history of hepatitis C virus in East Asia. J Virol 83: 1071-1082 doi:10.1128/jvi.01501-08.
14. Tobler LH, Bahrami SH, Kaidarova Z, Pitina L, Winkelman VK, et al. (2010) A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion 50: 1513-1523 doi:10.1111/j.1537-2995.2010.02634.x.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965 doi:10.1016/S0140-6736(01)06102-5.
16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401 doi:10.1038/nature08309.
17. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801 doi:10.1038/nature08463.
18. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S, (2013) Meta-analysis: implications of interleukin-28B polymorphism in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 11: 6 doi:10.1186/1741-7015-11-6.
19. Allain JP, (1998) The status of hepatitis C virus screening. Transfus Med Rev 12: 46-55 doi:10.1016/S0887-7963(98)80089-8.
20. Alter MJ, Kuhnert WL, Finelli L, (2003) (2003) Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 52: 12-5.
21. Delieu E, Perry KR, Parry JV (2002) Access®HCV Ab PLUS. MDA Evaluation Report: 20027 HMSO:ISBN 1 84182517 4.
22. WHO: Geneva (2001) Hepatitis C assays: operational characteristics. Report 1 [Internet].
23. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, et al. (2005) Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 45: 133-140 doi:10.1111/j.1537-2995.2004.04279.x.
24. Perry KR, Burgess CS, Ogunade OF, Parry JV, Rogers P (2001) Monolisa anti-HCV PLUS versions 1 and 2. MDA Evaluation Report 01001. HMSO- ISBN 1 84182 306 6.
25. McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, et al. (1990) Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet 335: 754-757 doi:10.1067/mpd.2003.45.
26. Van der Poel CL, Cuypers HT, Reesink HW, Weiner AJ, Quan S, et al. (1991) Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337: 317-319 doi:10.1016/0140-6736(91)90942-I.
27. Kim HS, (2009) Anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia. The Korean J Intern Med 24: 299-301 doi:10.3904/kjim.2009.24.4.299.
28. Seo YS, Jung ES, Kim JH, Jung YK, An H, et al. (2009) Significance of anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia. Korean J Intern Med 24: 302-308 doi:10.3904/kjim.2009.24.4.302.
29. Tibbs CJ, Palmer SJ, Coker R, Clark SK, Parsons GM, et al. (1991) Prevalence of hepatitis C in tropical communities: The importance of confirmatory assays. J Med Virol 34: 143-147 doi:10.1002/jmv.1890340302.
30. Yamaguchi K, Inaoka T, Ohtsuka R, Akimichi T, Hongo T, et al. (1993) HTLV-I, HIV-I, and hepatitis B and C viruses in Western Province, Papua New Guinea: a serological survey. Jpn J Cancer 84: 715-719.
31. WHO, Regional Committee for the Western Pacific (1999) Hepatitis and Related Disease. WPR/RC50/9.
32. Furusyo N, Hayashi J, Kakuda K, Sawayama Y, Ariyama I, et al. (1999) Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. Am J Trop Med Hyg 79: 85-91.
33. Lucas RE, Faoagali JL, (1999) The serological status of Solomon Island blood donors. The Southeast Asian J Trop Med Public Health 30: 542-545.
34. Rezza G, Danaya RT, Wagner TM, Sarmati L, Owen IL, et al. (2001) Human herpesvirus-8 and other viral infections, Papua New Guinea. Emerg Infect Dis 7: 893-895 doi:10.3201/eid0705.010522.
35. Armstrong GL, Williams IT, Maga UA, Viali S, Kuhnert WL, et al. (2006) Hepatitis C virus infection in Samoa and American Samoa. Am J Trop Med Hyg 74: 261-262.
36. Ott JJ, Stevens GA, Groeger J, Wiersma ST, (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212-2219 doi:10.1016/j.vaccine.2011.12.116.
37. WHO (2010) Viral Hepatitis: Global Policy.
38. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345 e1-7 doi:org/10.1053/j.gastro.2009.12.056. e1331-1337.
39. Lavanchy D, (2011) Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 17: 107-115 doi:10.1111/j.1469-0691.2010.03432.x.
40. Kelly A, Mathers B, Vallely A (2012) Emerging HIV risk in Papua New Guinea. Report. Joint: Papua New Guinea Institute of Medical Research and University of New South Wales.
41. Allain JP, (2005) Hepatitis C virus in blood donation. Lancet 365: 276-278 doi:10.1016/S0140-6736(05)17801-5.
42. Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, et al. (2011) IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis 204: 1843-1847 doi:10.1093/infdis/jir647.
43. Tobler LH, Tegtmeier G, Stramer SL, Quan S, Dockter J, et al. (2000) Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays:justification and rational implementation. Transfusion 40: 15-24 doi:10.1046/j.1537-2995.2000.40010015.x.